Completed NA INTERVENTIONAL 2-arm NCT03659058

Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR (fib-reversal)

Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After Achieving Sustained Virological Response

Sponsor: Zagazig University

Conditions Fibrosis, Liver

Interventions Antioxidants Colchicine FOLLOW UP Ursodeoxycholic Acid silymarin

Updated 5 times since 2018 Last updated: Nov 23, 2018 Started: Mar 2, 2016 Primary completion: Aug 31, 2018 Completion: Aug 1, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Fibrosis, Liver and is currently completed. Zagazig University leads this study, which shows 5 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Dec 2018 — Jan 2021 [monthly]

Completed NA
Oct 2018 — Dec 2018 [monthly]

Completed NA

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zagazig University

Data source: Zagazig University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.